Effectiveness of remote home monitoring for patients with Chronic Obstructive Pulmonary Disease (COPD): systematic review

Fernanda Inagaki Nagase1, Tania Stafinski1, Melita Avdagovska1, Michael K. Stickland2,3,4, Evelyn Melita Etruw5 and Devidas Menon1*

Abstract

Background: Although remote home monitoring (RHM) has the capacity to prevent exacerbations in patients with chronic obstructive pulmonary disease (COPD), evidence regarding its effectiveness remains unclear. The objective of this study was to determine the effectiveness of RHM in patients with COPD.

Methods: A systematic review of the scholarly literature published within the last 10 years was conducted using internationally recognized guidelines. Search strategies were applied to several electronic databases and clinical trial registries through March 2020 to identify studies comparing RHM to ‘no remote home monitoring’ (no RHM) or comparing RHM with provider’s feedback to RHM without feedback. To critically appraise the included randomized studies, the Cochrane Collaboration risk of bias tool (ROB) was used. The quality of included non-randomized interventional and comparative observational studies was evaluated using the ACROBAT-NRSI tool from the Cochrane Collaboration. The quality of evidence relating to key outcomes was assessed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE) on the following: health-related quality of life (HRQoL), patient experience and number of exacerbations, number of emergency room (ER) visits, COPD-related hospital admissions, and adherence as the proportion of patients who completed the study. Three independent reviewers assessed methodologic quality and reviewed the studies.

Results: Seventeen randomized controlled trials (RCTs) and two comparative observational studies were included in the review. The primary finding of this systematic review is that a considerable amount of evidence relating to the efficacy/effectiveness of RHM exists, but its quality is low. Although RHM is safe, it does not appear to improve HRQoL (regardless of the type of RHM), lung function or self-efficacy, or to reduce depression, anxiety, or healthcare resource utilization. The inclusion of regular feedback from providers may reduce COPD-related hospital admissions. Though adherence RHM remains unclear, both patient and provider satisfaction were high with the intervention.

Conclusions: Although a considerable amount of evidence to the effectiveness of RHM exists, due to heterogeneity of care settings and the low-quality evidence, they should be interpreted with caution.

Keywords: COPD, Remote monitoring, Home-based, Systematic review

Background

Chronic obstructive pulmonary disease (COPD) is a common, preventable lung disease characterized by long-term breathing problems and poor airflow due to airway and alveolar dysfunction commonly caused by smoking...
COPD is one of the leading causes of morbidity and mortality worldwide, with a substantial economic and social burden on individuals and society [2, 3]. Patients with COPD often suffer from comorbid diseases including heart failure, diabetes, and depression, making management of these patients complex and multifactorial [4].

Previous studies have shown that acute exacerbation are common in patients with COPD, and increasing frequency of exacerbations is associated with a decrease in lung function [5, 6], and an increase in the use of health services [7]. Integrating remote home monitoring (RHM) into clinical care may support patient self-management, and lead to improvements in symptoms and quality of life, while reducing COPD exacerbations burden and healthcare utilization [1, 2, 8–10]. Tomasic et al. have described remote monitoring as encompassing “automatic continuous physiological data transmission and processing decision support, the prediction of deterioration and alarming” [9]. Although, RHM has the capacity to prevent exacerbations, evidence concerning its safety and effectiveness remains unclear. Therefore, the objectives of this study was to determine the effectiveness of RHM programs for patients with COPD. This study was part of a project commissioned by Alberta Health to optimize care of patients with COPD in Alberta, Canada.

Methods
A systematic review of peer-reviewed primary studies was conducted following the Cochrane Handbook and Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines [11, 12].

Search strategy
An experienced medical information specialist in consultation with the research team iteratively developed a comprehensive, structured search strategy. It was peer-reviewed by another senior information specialist for quality assurance using the Peer Review of Electronic Search Strategies (PRESS) checklist [13]. The search strategy was applied to the following databases: Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Health Technology Assessment and the NHS Economic Evaluation Database. We also searched CINAHL and EconLit on the Ebsco platform and Web of Science. Details of the search strategy are presented in online supplementary Table S1. The search was conducted from March 1st to March 13th, 2020. The electronic searches were also supplemented by manual searches of reference lists from included studies. Results from the search strategy were compiled into Reference Manager which was used to manage all references.

Eligibility criteria
Two reviewers independently screened the titles and abstracts of all citations to identify studies for a full review. Full papers corresponding to potentially relevant citations were retrieved, divided among, and assessed by three reviewers for inclusion/exclusion according to criteria (Table 1). Although RCTs are considered the gold standard in assessing interventions under specific settings, observational studies may provide evidence on the effectiveness of RHM compared to usual care in the “real world”. As this study was commissioned to inform policy decisions, studies were not excluded based on design and quality. Reviewers met to compare results and agree on the final set of studies to include. At both screening steps, consensus between reviewers was assessed using the Kappa statistics and found to be “substantial”.

Data extraction and synthesis
Extracted data were tabulated to identify trends or patterns across studies and facilitate qualitative and quantitative comparative analyses. Key characteristics of included studies, their quality, potential sources of bias, and findings were synthesized narratively. A narrative synthesis of effectiveness outcomes across the studies was undertaken. Analysis was based on the types of technologies used for home monitoring which were grouped into three groups: (1) smartphones, apps, tablets; (2) dedicated home monitoring devices; (3) phone calls and text messages. Additionally, studies were assessed to determine whether patient populations, designs, and outcomes were similar enough to perform meta-analyses. Results were pooled if outcomes were assessed with the same measures and follow-up times. Heretogeneity was assumed to be too substantial to pool data when the I² statistic was equal to or greater than 50% [11]. Forest plots were used to display individual and pooled results. A p value < 0.05 was considered statistically significant in all analyses. Pooled risk ratios for categorical data and mean differences with 95% confidence intervals (CIs) for continuous outcomes were reported. Publication bias was assessed using funnel plots, where sufficient data (i.e. at least ten studies) were available from the meta-analyses [14]. Multiple studies published with an overlap of outcomes and patients were combined.

Assessment of study quality
RCTs were appraised using the Cochrane Collaboration Risk of Bias tool (ROB) [15]. The methodological quality of the non-RCT intervention and comparative observational studies were evaluated using the Cochrane Risk of Bias Assessment Tool for Non-Randomized Studies (ACROBAT-NRSI [16]. The quality of evidence relating
to key outcomes of interest were assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tool [17]. Prior to conducting the systematic review, a small questionnaire was conducted with members of an Expert Advisory Group (EAG) to rank the outcomes according to their importance. The six outcomes with the highest rank were included in the GRADE assessment [11, 18]. The EAG was arranged to oversee the project and involved clinicians, COPD program coordinators, policy makers and researchers. In this review, GRADE assessment was conducted by two independent reviewers and based on the following outcomes: health-related quality of life (HRQoL), patient experience and number of exacerbations, number of emergency room (ER) visits, COPD-related hospital admissions, and adherence as the proportion of patients who completed the study. Discrepancies between the reviewers were resolved through discussion.

### Results

#### Search results

Four thousand nine hundred ninety-three discrete citations were identified through the literature searches and screened, of which 239 were retrieved for full consideration. Twenty papers met the criteria for inclusion in the review. They comprised 17 RCTs and 2 comparative observational studies. Literature search results described using the PRISMA flow diagram are shown in Fig. 1.

#### Characteristics of studies

Seventeen [19–35] of the 19 studies [19–38] compared remote home monitoring (RHM) to ‘no remote home monitoring’ (no RHM), and two [36, 37] compared RHM with provider’s feedback to RHM without feedback. The 19 studies were conducted between 2006 and 2018 and had sample sizes ranging from 34 to 1,238 patients (details of participants’ characteristics included in the studies are presented in online supplementary Table S3). Collectively, they included 3,144 patients with COPD. Ten studies [19–22, 25, 26, 30, 32, 34, 35] recruited patients from multiple centres, and one [21] spanned five European countries (Spain, the United Kingdom, Slovenia, Estonia and Sweden). The remaining eighteen studies were conducted in Australia (2) [24, 27], Canada (1) [30], Denmark (1) [32], Germany (2) [28, 37], Hong Kong (1) [31], Italy (1) [25], Netherlands (3) [20, 22, 23], South

### Table 1 Remote Home Monitoring PICOS elements of the clinical effectiveness review protocol

| Parameter | Inclusion Criteria | Exclusion Criteria |
|-----------|--------------------|--------------------|
| **Participants** | Patients With COPD | Patients with Asthma  
No patients (simulation studies) |
| **Intervention** | Remote home monitoring (home is defined as independent or supportive living environments) | Remote home monitoring programs for patients living in Long Term Care Facilities or Nursing Homes  
Remote monitoring that is part of an outpatient program delivered in a hospital or community setting  
Remote monitoring that is part of an inpatient program |
| **Comparator** | Usual care (patients managed by their General Practitioner, specialist or both according to local practices) | Studies without any defined clinical outcomes  
Studies with no relevant clinical outcomes |
| **Outcomes** | Health-related quality of life  
Patient experience  
Frequency of exacerbations  
Healthcare resource utilization  
Hospital admissions  
ER visits  
Physician visits  
Adherence to/ compliance with treatment  
Safety  
Exercise capacity and activity levels  
Mental Health  
Self-efficacy  
Cost per patient  
Provider experience  
Lung function and symptoms | |
| **Study Design** | Comparative studies  
Randomized and non-randomized controlled trials (RCTs and non-RCTs)  
Cohort studies  
Case–control studies | Non-English language  
Expert reviews  
Editorials and opinion pieces  
Studies published prior to 2010 |
Korea (1) [19], Spain (2) [26, 29], the United Kingdom (1) [33], and the United States (3) [34–36] (Table 2).

**RHM program characteristics**

The length of the monitoring period varied from one to 12 months (comparison of what was monitored remotely and when in the included studies is presented in Table 3). At the beginning of the program, nurses taught patients how to use the technology, typically in patients’ homes. However, two studies [19, 20] held group sessions at outpatient clinics and two studies [22, 23] trained patients in their homes and outpatient clinics. In four studies [19, 20, 23, 24], patients also participated in outpatient group education and exercise sessions (a detailed description of the home monitoring program, technology and its components is presented in online supplementary Tables S4, S5, and S6).

Comparator interventions in the studies were ‘no RHM,’ or RHM without feedback and alerts from healthcare providers. ‘No RHM’ generally comprised usual care based on local practices, in which patients were instructed to contact their healthcare provider if they experienced worsening of symptoms. Five studies [19, 20, 24, 27, 32] reported that patients in the ‘no RHM’ group received education and exercise training sessions or materials similar to those received by the RHM group. RHM without feedback and alerts consisted of patients measuring parameters and transmitting data, but with no healthcare providers’ feedback.

The RHM technology and integrated peripheral devices varied across studies; most of the interventions had a dedicated device for home monitoring. Four studies [19, 20, 22, 23] used smartphones and apps as the main device, and in one study [19], education material and exercise training were also available through the app. One study [21] used a tablet to facilitate recording and transmission of data. Two studies [36, 37] used telephone and text messages to monitor patients. Included integrated peripheral devices were: pulse oximeter (in 11 studies) [20, 21, 24–27, 29, 31–33, 35], blood pressure
Table 2  Characteristics of included studies

| Study (country) | Study period (Design) | Study objective | Eligibility criteria | Number of centres | Number of participants | Follow-up | Outcomes |
|----------------|-----------------------|-----------------|----------------------|-------------------|-----------------------|-----------|----------|
| RHM (smartphones, apps, tablets) vs no RHM |
| Park 2020 (South Korea) [19] | Mar 2016- Jun 2018 (RCT) | To examine the effect of a smartphone app-based, self-management program on self-care behavior | Inclusion criteria:  
  - Age ≥ 45 years old  
  - Mild, moderate or severe COPD  
  - Had a smartphone and could text messages  
  - Able to communicate  
Exclusion criteria:  
  - Psychiatric disorder  
  - COPD-related hospitalization in the last 2 months  
  - Exacerbation  
  - Oxygen saturation < 93% in a stable state or < 85% after a six minute walk test  
  - Severe respiratory symptoms in a stable state  
  - Attended PR in the previous year  
  - Other diseases that made physical activity and/or exercise difficult  
  - Use of assistive devices to walk or problems with balance | Multiple centres | RHM: 23  
no RHM: 21 | 6 months | • Adherence  
• ER visits  
• Exacerbations  
• Exercise capacity and activity levels  
• Health-related quality of life  
• Hospital admissions  
• Lung function and other symptoms  
• Mental health  
• Patient experience  
• Safety  
• Self-efficacy  
• Visits to physician |
| Boer 2019 (Netherlands) [20] | Jun 2015- Jul 2016 (RCT) | To examine the effects of a smart mobile health (mHealth) tool that supports COPD patients in the self-management of exacerbations | Inclusion criteria:  
  - Age ≥ 40 years old  
  - Spirometry-confirmed diagnosis of COPD (FEV1/FEVC < 70%)  
  - 2 or more exacerbations in the last year  
  - Had experienced 2 or more symptom-based exacerbations  
Exclusion criteria:  
  - Severe comorbid conditions that prohibited safe participation  
  - Insufficient knowledge of the Dutch language  
  - Persisting difficulties in using the mHealth system after a 2-week practice period and additional assistance | Multiple centres | RHM: 43  
no RHM: 44 | 12 months | • Adherence  
• Exacerbations  
• Health-related quality of life  
• Hospital admissions  
• Lung function and other symptoms  
• Mortality  
• Patient experience  
• Self-efficacy  
• Visits to physician |
Table 2 (continued)

| Study (country) | Study period (Design) | Study objective | Eligibility criteria | Number of centres | Number of participants | Follow-up | Outcomes |
|----------------|-----------------------|----------------|----------------------|-------------------|-----------------------|----------|----------|
| Walker 2018 (Spain, UK, Slovenia, Estonia, Sweden) [21] | Oct 2013- Apr 2016 (RCT) | To evaluate the effectiveness of remote monitoring in reducing healthcare utilization | **Inclusion criteria:**  
  • Age ≥ 60 years old  
  • Moderate to very severe diagnosis of COPD  
  • Acute exacerbation with or without hospitalization in the previous year  
  • Smoking history of ≥ 10 pack-years  
  • One or more chronic conditions (congestive heart failure, ischemic heart disease, hypertension, hyperlipidemia and clinically significant sleep-disordered breathing)  
  • Clinically stable, with at least 4 weeks since the last exacerbation  
  **Exclusion criteria:**  
  • Significant visual disturbance or mental health disorders  
  • Planned prolonged absence from home  
  • Living in areas not covered by a mobile data network  
  • Unable to use the study equipment | Multiple centres | RHM: 154  
  no RHM: 158 | 9 months |  
  • Adherence  
  • Cost  
  • Exacerbations  
  • Health-related quality of life  
  • Hospital admissions  
  • Length of hospitalization  
  • Mental health  
  • Mortality |
| Study (country) | Study period (Design) | Study objective | Eligibility criteria | Number of centres | Number of participants | Follow-up | Outcomes |
|----------------|-----------------------|-----------------|----------------------|-------------------|-----------------------|-----------|----------|
| Tabak 2014a (Netherlands) [22] | Dec 2011- Jul 2013 (RCT) | To investigate the satisfaction and use of telehealth in patients with COPD | **Inclusion criteria:**  
- Age > 40 years old  
- Diagnosis of COPD based on the GOLD criteria  
- Internet access at home  
- Able to understand Dutch  
**Exclusion criteria:**  
- Age < 75 years old  
- Exacerbation in the previous month  
- Three or more exacerbations in the previous two years  
- One hospitalization for respiratory problems in the previous two years  
- Serious disease with low survival rates  
- Other diseases influencing bronchial symptoms and/or lung function (e.g., cardiac insufficiency, sarcoidosis)  
- Severe psychiatric illness  
- Uncontrolled diabetes mellitus | Multiple centres | RHM: 15  
no RHM: 14 | 9 months | • Adherence  
• ER visits  
• Exacerbations  
• Exercise capacity and activity levels  
• Health-related quality of life  
• Hospital admissions  
• Length of hospitalization  
• Lung function and other symptoms  
• Patient experience |
| Tabak 2014b (Netherlands) [23] | Oct 2010- Apr 2011 (RCT) | To assess the effectiveness of telerehabilitation in patients with COPD | **Inclusion criteria:**  
- Current or former smoker  
- Able to read and speak Dutch  
- Internet access at home  
**Exclusion criteria:**  
- Infection or exacerbation in the previous month  
- Impaired hand function causing inability to use the intervention  
- Disorders or progressive disease seriously influencing daily activities (e.g. amputation)  
- Other diseases influencing bronchial symptoms and/or lung function (e.g. sarcoidosis)  
- Regular oxygen therapy (> 16 h per day or pO2 < 7.2 kPa)  
- Asthma  
- Attended physiotherapy in the last six weeks | NR | RHM: 18  
no RHM: 16 | 1 month | • Adherence  
• Exercise capacity and activity levels  
• Health-related quality of life  
• Lung function and other symptoms |
| Study (country)     | Study period (Design) | Study objective                                                                 | Eligibility criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Number of centres | Number of participants | Follow-up | Outcomes                                                                 |
|--------------------|-----------------------|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------|-----------|--------------------------------------------------------------------------|
| RHM (dedicated monitoring devices) vs no RHM |                       |                                                                                |                                                                                                               |                                                                 |                   |                       |           |                                                                                                                                      |
| Shany 2017 (Australia) [24] | Mar 2009- Oct 2010 (RCT) | To investigate the effects of home telemonitoring in patients with severe COPD | Inclusion criteria:  
- At least one hospital admission for an exacerbation in the last year  
Exclusion criteria:  
- Insufficient English fluency  
- Motor deficits that might prevent the use of the telehealth  
- Cognitive impairment  
- Participation in another trial  
- No landline phone connection at home  
- Inclusion criteria:  
- At least one hospital admission for an exacerbation in the last year  
- Exclusion criteria:  
- Insufficient English fluency  
- Motor deficits that might prevent the use of the telehealth  
- Cognitive impairment  
- Participation in another trial  
- No landline phone connection at home  | Single centre | RHM: 21 no RHM: 21 | 12 months | • Adherence  
• Cost  
• ER visits  
• Hospital admissions  
• Length of hospitalization  
• Mental health  
• Mortality  
• Patient experience  
• Provider experience |
| Vianello 2016 (Italy) [25] | Nov 2011- May 2014 (RCT) | To investigate the benefits of a telemonitoring system in managing acute exacerbation advanced-stage COPD patients | Inclusion criteria:  
- Age ≥ 18 years old  
- Severe to very severe diagnosis of COPD  
- Life expectancy > 12 months  
- Capability of using, alone or assisted, the intervention  
Exclusion criteria:  
- Concomitant significant lung disease  
- Negative advice of the GP  
- Serious social problems, including lack of adequate family support and/or other social support networks  | Multiple centres | RHM: 230 no RHM: 104 | 12 months | • Adherence  
• ER visits  
• Health-related quality of life  
• Hospital admissions  
• Length of hospitalization  
• Mental health  
• Mortality  
• Visits to physician |
| Segrelles 2014 (Spain) [26] | Jan 2010- Jul 2011 (RCT) | To assess the efficacy and effectiveness of a home telehealth program for COPD patients with severe airflow obstruction | Inclusion criteria:  
- Age ≥ 50 years old  
- Severe to very severe diagnosis of COPD (FEV₁ < 50% predicted, FEV₁/FVC ratio < 70%)  
- Long-term home oxygen therapy  
Exclusion criteria:  
- Current smoker  
- Enrolled in a palliative care program  
- Institutionalized or at risk of social exclusion  
- Unable to understand all procedures  | Multiple centres | RHM: 30 no RHM: 30 | 7 months | • Adherence  
• ER visits  
• Hospital admissions  
• Length of hospitalization  
• Mortality |
| Study (country) | Study period (Design) | Study objective | Eligibility criteria | Number of centres | Number of participants | Follow-up | Outcomes |
|----------------|----------------------|-----------------|----------------------|-------------------|-----------------------|-----------|----------|
| De San Miguel 2013 (Australia) [27] | NR (RCT) | To understand the impact of telehealth monitoring for COPD patients on health service utilization and cost-effectiveness | **Inclusion criteria:**  
- Diagnosis of COPD  
- Use of home oxygen therapy  
- Able to speak English  
- Palliative care  
- No telephone landline  
- Unable to use telehealth equipment due to cognitive impairment or physical disability | Single centre | RHM: 40 no RHM: 40 | 6 months | - Cost  
- ER visits  
- Health-related quality of life  
- Hospital admission  
- Length of hospitalization  
- Patient experience  
- Visits to physician |
| Jehn 2013 (Germany) [28] | Jan 2012 - Jan 2013 (RCT) | To determine if the use of home monitoring reduces risk of exacerbations due to changes in the weather | **Inclusion criteria:**  
- Age ≥ 40 years old  
- Moderate to very severe diagnosis of COPD (FEV₁ < 80% predicted and FEV₁/FVC ratio < 70%)  
- At least one exacerbation in the previous year  
- Clinically stable for the last month | Single centre | RHM: 32 no RHM: 30 | 9 months | - Adherence  
- Exacerbations  
- Exercise capacity and activity levels  
- Health-related quality of life  
- Hospital admissions  
- Length of hospitalization  
- Lung function and other symptoms  
- Visits to physician |
| Study (country) | Study period (Design) | Study objective | Eligibility criteria | Number of centres | Number of participants | Follow-up | Outcomes |
|----------------|-----------------------|----------------|----------------------|-------------------|-----------------------|-----------|----------|
| Jodar-Sanchez 2013 (Spain) [29] | Sep 2010- May 2011 (RCT) | To analyze the effectiveness of a telehealth programme in patients with advanced COPD | **Inclusion criteria:**  
- Adult  
- Diagnosis of COPD  
- Long-term oxygen therapy  
- At least one hospitalisation for respiratory illness in the previous year  
- Clinically stable during the previous three months  
- **Exclusion criteria:**  
- No home telephone line | Single centre | RHM: 24 no RHM: 21 | 4 months | • Adherence  
• ER visits  
• Health-related quality of life  
• Hospital admissions  
• Length of hospitalization  
• Mortality  
• Patient experience  
• Provider experience  
• Visits to physician |
| Pare 2013 (Canada) [30] | Sep 2010- Oct 2011 (RCT) | To assess the effectiveness of home monitoring in reducing costs associated with managing COPD | **Inclusion criteria:**  
- Very serious COPD requiring frequent home visits (FEV1 < 45% predicted)  
- At least one hospitalisation in the previous year  
- Willingness to manage their health status (with or without an informal caregiver)  
- Able to communicate in English or French  
- An operational telephone line at the home  
- **Exclusion criteria:**  
- Suffered from psychological or psychiatric problems  
- Cognitive deficit  
- Visual or motor deficit that would unable the use of the intervention unless an informal caregiver agreed to assist | Multiple centres | RHM: 60 no RHM: 60 | Pre-phase: 12 months Post phase: 12 months | • Cost  
• ER visits  
• Hospital admissions  
• Length of hospitalization  
• Patient experience |
| Chau 2012 (Hong Kong) [31] | 2010- NR (RCT) | To examine user satisfaction and effectiveness of telecare services in patients with COPD | **Inclusion criteria:**  
- Age ≥ 60 years old  
- Moderate or severe COPD  
- At least one hospital admission due to exacerbation in the previous year  
- **Exclusion criteria:**  
- Impaired cognitive function  
- Illiterate  
- Hearing problems  
- Unable to operate the telecare device | Single centre | RHM: 30 no RHM: 23 | Mean RHM: 65.18 days no RHM: 68.44 days | • Adherence  
• ER visits  
• Health-related quality of life  
• Hospital admissions  
• Length of hospitalization  
• Lung function and other symptoms  
• Patient experience |
| Study (country) | Study period (Design) | Study objective | Eligibility criteria | Number of centres | Number of participants | Follow-up | Outcomes |
|----------------|-----------------------|-----------------|----------------------|-------------------|-----------------------|-----------|---------|
| Dinesen 2012 (Denmark) [32] | NR (RCT) | To test whether preventive home monitoring in COPD reduced the admission rate to hospital and the cost of hospitalization | **Inclusion criteria:**  
  - Age > 18 years old  
  - Diagnosis of severe or very severe COPD  
  - Able to understand oral and written information  
  **Exclusion criteria:**  
  - Heart disease that could limit physical activity  
  - Mental illness  
  - Terminal malignancy disease  
  - Severe rheumatoid arthritis  
  - Pregnancy | Multiple centres | RHM: 60 no RHM: 51 | 10 months | • Adherence  
  • Cost  
  • Hospital admissions |
| Lewis 2010 (UK) [33] | Nov 2007 – Mar 2009 (RCT) | To determine if telemonitoring in stable and optimized COPD patients affects their health care utilization | **Inclusion criteria:**  
  - Diagnosis of moderate to severe COPD  
  - Completed at least 12 out of 18 sessions of outpatient PR  
  - Have a GP  
  - Have a standard telephone line  
  **Exclusion criteria:**  
  - Chronic asthma and interstitial lung disease  
  - Unstable cardiac disease  
  - Cognitive impairments  
  - Other medical conditions that would unable the use of the intervention  
  - Living in nursing or residential institution  
  - Participation in any investigational drug trial in the last month  
  - Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study | Single centre | RHM: 20 no RHM: 20 | 12 months | • Adherence  
  • ER visits  
  • Health-related quality of life  
  • Hospital admissions  
  • Length of hospitalization  
  • Mental health  
  • Mortality  
  • Patient experience  
  • Visit to physician |
| Au 2015 (USA) [34] | 2006-2007 (Observational) | To examine the effects of telemonitoring on resource use among Medicare patients with COPD | **Inclusion criteria:**  
  - At least a diagnosis of COPD, congestive heart failure, or diabetes mellitus  
  **Exclusion criteria:**  
  - Comorbidities such as dementia or blindness that would limit interaction with the program | Multiple centre | RHM: 619 no RHM: 619 | 3 years | • Adherence  
  • ER visits  
  • Exacerbations  
  • Hospital admissions  
  • Length of hospitalization |
### Table 2 (continued)

| Module | Study period (Design) | Study objective | Eligibility criteria | Number of centres | Number of participants | Follow-up | Outcomes |
|--------|-----------------------|-----------------|----------------------|-------------------|-----------------------|-----------|----------|
| Multiple centres | RHM: 58 no RHM: 174 | 3 months | Adherence | ER visits | Health-related quality of life | Mortality | Patient experience |
| Single centre | RHM: 83 no RHM: 85 | 8 months | Adherence | Hospital admissions |

**RHIM with feedback (phone calls, text messages) vs RHIM with no feedback**

| Module | Study period (Design) | Study objective | Eligibility criteria | Number of centres | Number of participants | Follow-up | Outcomes |
|--------|-----------------------|-----------------|----------------------|-------------------|-----------------------|-----------|----------|
| Single centre | Total: 53a | 6 months | Adherence | Exercise capacity and activity levels | Health-related quality of life |

Notes: Tabak 2014a [22] and Tabak 2014b [23] used the same exercise monitoring device and smartphone technology. De San Miguel 2013 [27] and Lewis 2010 [33] used the same telemonitoring device. Segrelles 2014 [26] and Jodar-Sanchez 2013 [29] used the same devices to collect vital signs measures and modem technology to transmit collected measurements.

* Cross-over randomized trial

**COPD** Chronic obstructive pulmonary disease, **FEV** Forced expiratory volume in one second, **FVC** Forced vital capacity, **GP** General practitioner, **HF** Heart failure, **PR** Pulmonary rehabilitation, **RCT** Randomized controlled trial, **RHIM** Remote home monitoring
Table 3  Comparison of what was monitored remotely and when in the included studies

| Study                       | Frequency of monitoring                                      | Symptoms | Medication use | Oxygen saturation | Respiratory rate | Spirometry | Heart rate | Blood pressure | Temperature | Weight | Exercise |
|-----------------------------|--------------------------------------------------------------|----------|----------------|-------------------|------------------|-------------|------------|---------------|-------------|--------|----------|
| RHM (smartphones, apps, tablets) vs no RHM |                               |          |                |                   |                  |             |            |               |             |        |          |
| Park 2020* [19]             | • At least 4 times per week and when experiencing an exacerbation • Exercises were only recorded on days patients exercised | ✓        | ✓              | ✓                 | ✓                | ✓           |            |               |             |        |          |
| Boer 2019 [20]              | • Every time patient experienced a change in disease symptoms or burden | ✓        | ✓              | ✓                 | ✓                | ✓           | ✓          |               |             |        |          |
| Walker 2018 [21]            | • Daily                                                      | ✓        | ✓              | ✓                 |               |             |            |               |             |        |          |
| Tabak 2014a [22]            | • Daily                                                      | ✓        | ✓              | ✓                 | ✓                | ✓           | ✓          |               |             |        |          |
| Tabak 2014b [23]            | • Daily                                                      | ✓        | ✓              | ✓                 |               |             |            |               |             |        |          |
| RHM (dedicated monitoring devices) vs no RHM |                               |          |                |                   |                  |             |            |               |             |        |          |
| Shany 2017* [24]            | • Daily                                                      | ✓        | ✓              | ✓                 | ✓                | ✓           | ✓          | ✓             | ✓           |        |          |
| Vanello 2016 [25]           | • Every other day and in the event of clinical worsening • Symptoms and medication use were reported only when requested by healthcare provider | ✓        | ✓              | ✓                 | ✓                | ✓           | ✓          |               |             |        |          |
| Segrelles 2014 [26]         | • Daily                                                      | ✓        | ✓              | ✓                 | ✓                | ✓           | ✓          |               |             |        |          |
| De San Miguel 2013 [27]     | • Daily                                                      | ✓        | ✓              | ✓                 | ✓                | ✓           | ✓          |               |             |        |          |
| Jehn 2013 [28]              | • Daily in the morning during a specified 2 h window • Exercise was monitored weekly in the morning during a specified two-hour window | ✓        | ✓              | ✓                 |               |             |            |               |             |        |          |
| Jodar-Sanchez 2013 [29]     | • Daily • Pulmonary function was measured twice a week       | ✓        | ✓              | ✓                 | ✓                | ✓           | ✓          |               |             |        |          |
| Pare 2013 [30]              | • Daily                                                      | ✓        | ✓              |                   |                  |             |            |               |             |        |          |
| Chau 2012 [31]              | • Daily (three times a day)                                  | ✓        | ✓              | ✓                 |               |             |            |               |             |        |          |
| Dinesen 2012 [32]           | • As prescribed by physician                                | ✓        | ✓              | ✓                 | ✓                | ✓           | ✓          |               |             |        |          |
| Lewis 2010 [33]             | • Daily (twice a day at specified times)                    | ✓        | ✓              | ✓                 |               |             |            |               |             |        |          |
| Au 2015 [34]                | • Daily                                                      | ✓        | ✓              |                   |                  |             |            |               |             |        |          |
| Davis 2015 [35]             | • Daily                                                      | ✓        | ✓              |                   |                  |             |            |               |             |        |          |
| Study               | Frequency of monitoring                                                                 | Symptoms | Medication use | Oxygen saturation | Respiratory rate | Spirometry | Heart rate | Blood pressure | Temperature | Weight | Exercise |
|---------------------|----------------------------------------------------------------------------------------|----------|----------------|-------------------|------------------|-------------|------------|----------------|-------------|--------|----------|
| Sink 2018 [39]      | • Daily                                                                                 | ✓        |                |                   |                  |             |            |                |             |        |          |
|                     | • Frequency reduced to twice a week if no worsening of symptoms for 30 consecutive days |          |                |                   |                  |             |            |                |             |        |          |
|                     | • Frequency temporarily resumed to daily if breathing assessment detected a worsening in breathing |          |                |                   |                  |             |            |                |             |        |          |
| Franke 2016 [37]    | • Daily                                                                                 | ✓        |                |                   |                  |             |            |                |             |        |          |

*RHM with feedback (phone calls, text messages) vs RHM with no feedback*
In the majority of studies, patients were asked to collect data daily. The most common parameters monitored were symptoms (15), oxygen saturation (11), weight scale (4), and lung function (8). All studies reported that transmission of data occurred immediately. In ten studies, healthcare providers or nurses were responsible for monitoring data. Four studies used a central management unit to monitor data and five used algorithms and decision trees to monitor and detect changes in symptoms and clinical parameters. In most studies, healthcare providers or nurses contacted patients if clinical worsening was observed and/or data were not recorded for several days. None of the studies discussed data privacy.

Risk of bias

Results of risk of bias assessment

Quality assessment was conducted for the seventeen RCTs and two non-randomized studies (detailed description in online supplementary Table S7).

RCTs Six studies (19–21, 23, 25, 27) assigned patients to treatment groups via a computer-generated sequence and three (31, 32, 40) used drawing of lots. Four trials (23, 29, 33, 36, 38) were likely at high risk of selection bias since three (23, 29, 33, 38) reported an unequal distribution of patients’ characteristics between groups, and one [36] had assigned seventeen patients to the control group without randomization. Only five (23, 26, 30, 32, 33, 38) provided details around allocation concealment. Four (23, 30, 32, 33, 38) adhered to adequate methods for keeping patients and investigators unaware of treatment allocation prior to assignment. One study [26] randomized the clinics, rather than patients themselves. Due to the nature of remote monitoring, neither patient nor staff were blinded to the intervention. Thus, the risk of performance bias was high. Patient reported outcomes were also at high risk of observer bias because patients were the assessors and not blinded to the type of intervention they had received. Eight studies [20–22, 24, 25, 32, 36, 37] were at low risk of observer bias. Six RCTs [22, 26, 28–30, 33, 38] provided insufficient information to determine the presence of observer bias. Four RCTs [23, 24, 31, 36] were at high risk of attrition bias. Three studies reported differences in the frequency of missing data and reasons for dropouts between groups. The risk of attrition bias was low in eleven of the RCTs [19–22, 25–30, 32], where the extent of missing data was small and similar between groups. Two studies [33, 37, 38] did not provide sufficient information to determine the risk of attrition bias. Ten trials [19, 22–24, 27–32] did not publish or register their protocols and five [19, 32, 33, 37, 38] were considered to have an incomplete follow-up data on outcome measures described in trial registrations and study methods sections (Figs. 2 and 3).

Non-randomized studies

Both non-randomized studies were at serious risk of bias due to confounding and patient selection. They used methods to adjust for socioeconomic variables, but did not measure and adjust for clinical confounders (e.g. FEV1, severity of COPD). Further, recruitment into these studies was based on availability of the technology and patients’ preferences [34, 35]. One non-randomized study [34] measured objective outcomes unlikely to be influenced by knowledge of the intervention received. The second non-randomized study [35] did not blind the outcome assessor to intervention type. However, in both of these studies, the intervention status remained the same throughout their duration, minimizing the risk of bias in the measurement of interventions. In the two non-randomized studies [34, 35], data were reasonably complete. None of the non-randomized studies [34, 35] discussed the care received by the comparator group (Figs. 4 and 5).

Results from GRADE assessment

GRADE assessment was conducted on the selected outcomes (Tables 4, 5 and 6). The GRADE level or certainty of the evidence for these outcomes was very low to low for all outcomes in studies comparing RHM (smartphones, apps, tablets) to no RHM, RHM (dedicated monitoring devices) to no RHM, and RHM (phone calls, text messages) to no RHM.

Summary results of effectiveness

Health-related quality of life (HRQoL)

RHM (smartphones, apps, tablets) versus no RHM Two studies [20, 23] that measured changes in HRQoL from baseline using the CCQ reported no statistically significant differences between groups. Across studies [19–21, 23] that used other HRQoL measures (SF-36, NCSI, and EQ-5D), there were no statistically significant differences between changes in the two groups.

RHM (dedicated monitoring devices) versus no RHM None of the studies comparing RHM with no RHM showed a statistically significant difference between...
groups in the change in HRQoL over time, regardless of the instrument used (CAT, CRQ, SGRQ or EQ5D) [25, 27, 29, 33, 38].

**RHM with feedback vs RHM without feedback** After 6 months, CAT scores had statistically significantly improved within both groups in the cross-over RCT suggesting that the feedback component had minimal to no effect on HRQoL [37] (details are presented in online supplementary Tables S8, S9 and S10).

**Patient experience**

**RHM (smartphones, apps, tablets) versus no RHM** Three studies [19, 20, 22] that examined patient experiences
and satisfaction with RHM demonstrated comparably high satisfaction levels.

RHM (dedicated monitoring devices) versus no RHM Seven studies [24, 27, 29–31, 33, 35] explored patients’ experiences with the dedicated monitoring devices. Few difficulties with the devices were reported. In general, patients felt the technology was easy to operate and were satisfied with the support received when troubleshooting clinical and technical problems. Six studies [24, 27, 29–31, 35] assessed perceived benefits related to RHM. They included: better control over/management of their disease, less anxiety, improved ability to cope with their disease, and reduced burden on family members. In all five studies [24, 30, 31, 33, 35] that measured overall satisfaction, the proportion of patients satisfied was high – at least 80% were reported (details presented in online supplementary Table S11).
Frequency of exacerbations

**RHM (smartphones, apps, tablets) versus no RHM**

No difference was reported [20, 21].

**RHM (dedicated monitoring devices) versus no RHM**

One study [28] reported a statistically significantly higher number in the no RHM group, but the larger study [34] found no difference between groups.

---

Table 4  Studies comparing remote home monitoring (smartphones, apps, and tablets) to no remote home monitoring

| Outcomes                                                                 | Nº of participants (studies) | Certainty of the evidence (GRADE) | Relative effect* (95% CI) | Anticipated absolute effects | Risk with no RHM | Risk difference with RHM (smartphones, apps, tablets) |
|--------------------------------------------------------------------------|------------------------------|-----------------------------------|---------------------------|-----------------------------|------------------|-----------------------------------------------------|
| COPD Assessment Test (CAT) scores at the end of monitoring period        | 312 (1 RCT)                  | LOW                              | not pooled                | not pooled                  | not pooled        | not pooled                                          |
| Patient experience- Overall satisfaction at the end of monitoring period  | 73 (2 RCTs)                  | VERY LOW                         | not pooled                | not pooled                  | not pooled        | not pooled                                          |
| Average number of exacerbations                                          | 87 (1 RCT)                   | LOW                              | not pooled                | not pooled                  | not pooled        | not pooled                                          |
| Average number of ER visits due to COPD                                  | 29 (1 RCT)                   | LOW                              | not pooled                | not pooled                  | not pooled        | not pooled                                          |
| Average number of hospital admissions due to COPD                        | 116 (2 RCTs)                 | LOW                              | not pooled                | not pooled                  | not pooled        | not pooled                                          |
| Adherence as the proportion of participants who completed the study      | 506 (5 RCTs)                 | LOW                              | not pooled                | not pooled                  | not pooled        | not pooled                                          |

1 The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)

CI Confidence interval, COPD Chronic obstructive pulmonary disease, ER Emergency room, RCT Randomized clinical trial, RHM Remote home monitoring

* Study(ies) at high risk of bias

b Small sample size
c Differences in point estimates
d The outcome is an indirect measure of compliance with intervention
Healthcare resource utilization (hospital admissions, ER visits, and physician visits)

**RHM (smartphones, apps, tablets) versus no RHM** The impact of RHM on healthcare resource utilization was assessed using numbers of hospital admissions due to COPD [19–21], ER visits [19, 22], and physician visits among patients who received or did not receive RHM [19, 20]. These were similar between groups (detailed description in online supplementary Table S12).

**RHM (dedicated monitoring devices) versus no RHM** Nine studies [24–28, 30, 31, 33, 34, 38] assessed the extent to which RHM with dedicated monitoring devices affected COPD-related hospitalizations. In seven studies, values were similar between groups [24, 25, 27, 28, 30, 31, 33, 38]. However in two studies [26, 34], there were statistically significantly fewer admissions in the RHM group. Of the five studies [25, 27–29, 33, 38] measuring visits to specialists or primary care physicians, four [25, 27, 29, 33, 38] found no statistically significant differences between groups in specialist or primary care physician visits. In one study [28], however, the number of visits to a primary care physician was higher among patients who did not receive RHM.

**RHM with feedback vs RHM without feedback** One study compared the total number of COPD-related hospital admissions over 8 months between treatment groups. The group who received continuous feedback on self-reported monitoring data from a healthcare provider had a statistically significantly lower number of admissions (over 8 months) than the group who did not [36].

**Adherence to/compliance with treatment**

**RHM (smartphones, apps, tablets) versus no RHM** In four studies [19–21, 23], adherence with treatment appeared to be similar between groups, but in the fifth
study [22], it was almost 5 times higher in the RHM group than in the comparator group (no RHM). Risk ratios for the two studies [21, 23] demonstrated conflicting results (Fig. 6).

### Table 6  Studies comparing remote home monitoring (phone calls, text messages) to no RHM

| Outcomes                                              | No of participants (studies) | Certainty of the evidence (GRADE) | Relative effect* (95% CI) | Anticipated absolute effects |
|-------------------------------------------------------|-----------------------------|-----------------------------------|---------------------------|-----------------------------|
| COPD Assessment Test (CAT) scores at the end of monitoring period | 106 (1 RCT)                | LOW                               | not pooled                | not pooled                  |
| Patient experience- Overall satisfaction at the end of monitoring period—not measured | -                           | -                                 | -                         | -                           |
| Average number of exacerbations—not measured          | -                           | -                                 | -                         | -                           |
| Average number of ER visits due to COPD— not measured | -                           | -                                 | -                         | -                           |
| Average number of hospital admissions due to COPD     | 168 (1 RCT)                | LOW                               | not pooled                | not pooled                  |
| Adherence as the proportion of participants who completed the study | 168 (1 RCT)                | VERY LOW                          | not pooled                | not pooled                  |

* The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)

CI: confidence interval; COPD: chronic obstructive pulmonary disease; ER: emergency room; RCT: randomized clinical trial; RHM: remote home monitoring

a Study at high risk of bias
b Small sample size
c Outcome is an indirect measure of compliance with intervention

**Fig. 6** Forest plot of risk ratios for treatment adherence at 9 months of follow-up

**Fig. 7** Forest plot of risk ratios for treatment adherence at 12 months of follow-up

**RHM (dedicated monitoring devices) versus no RHM**  In the studies, adherence with treatment appeared to be similar between groups. The exception was a small 12-month study [24] of 21 patients who received RHM...
and 21 patients who had usual care (no RHM) (Fig. 7) [24, 25].

**RHM with feedback vs RHM without feedback** One study [36] reported a 76% compliance for RHM and 68% for no RHM, but there was no information on the statistical significance of the difference.

**Safety**

One study [19] (RHM using smartphones, apps or tablets vs. no RHM) reported data on adverse events, and no statistically significant differences between treatment groups were found. Eight studies [20, 21, 24–26, 29, 33, 35, 38] reported deaths from all causes and were similar between treatment groups.

**Exercise capacity and activity levels**

**RHM (smartphones, apps, tablets) versus no RHM** Exercise capacity and activity levels improved statistically significantly in the RHM group, but the between groups difference was not statistically significant [19].

**RHM (dedicated monitoring devices) versus no RHM** Patients who received RHM statistically significantly increased the 6-min walk distance, but those in the no RHM group did not [28].

**RHM with feedback vs RHM without feedback** Total leisure activity at 6 months in patients who received RHM with feedback was statistically significantly higher than in the group without feedback (details presented in online supplementary Table S14) [37].

**Mental health**

**RHM (smartphones, apps, tablets) versus no RHM** Neither of two studies reported statistically significant changes in POMS or PHQ-9 (tension-anxiety and depression) scores within or between groups after 6 months [19, 21].

**RHM (dedicated monitoring devices) versus no RHM** No statistically significant differences in baseline or follow-up scores in validated measures in 2 studies [19, 20].

**Self-efficacy**

**RHM (smartphones, apps, tablets) versus no RHM** Neither of two studies reported statistically significant differences in self-efficacy measures between the RHM and usual care groups at baseline or at the end of the follow-up period [19, 20] (details are presented in online supplementary Table S16).

**Cost per patient**

**RHM (smartphones, apps, tablets) versus no RHM** In the single study [21] reporting per patient costs with and without RHM, no statistically significant differences were seen between groups.

**RHM (dedicated monitoring devices) versus no RHM** Two studies [24, 32] compared the cost of hospital admission and one [30] compared all costs (from 12 months prior to and 6 months after the start of RHM). All concluded that there were no statistically significant difference between groups (details presented in online supplementary Table S17).

**Provider experience**

None of the included studies reported on providers’ experiences involved in RHM (smartphones, apps, tablets) versus no RHM and RHM with feedback vs RHM without feedback comparisons.

**RHM (dedicated monitoring devices) versus no RHM** Two studies [24, 29] reported findings from surveys designed to obtain feedback from providers. Perceptions around the dedicated home monitoring device’s usability and value improved as provider experience increased; however, only six providers participated in the two studies (details presented in online supplementary Table S18).

**Lung function and symptoms**

**RHM (smartphones, apps, tablets) versus no RHM** No statistically significant differences in baseline or follow-up scores in validated measures in 2 studies [19, 20].

**RHM (dedicated monitoring devices) versus no RHM** In the two studies [28, 31], no statistically significant differences were found in predicted values for FEV₁ at baseline.
and at the end of follow-up between groups (details presented in online supplementary Table S19).

Discussion
Several aspects distinguish this work from previously published literature reviews [3, 41–46]. This review yielded more studies due to the broader inclusion criteria of home monitoring technology and its components, outcomes, and types of included studies. For example, previous systematic reviews included small numbers of studies (between 3 [41] and 10 [42]). Further, previous reviews measured a relatively small number of outcomes [45], had unclearly defined outcomes [3], had a substantive difference between defined and measured outcomes [41], or considered satisfaction from the patient perspective only [42, 46]. In the current review, in addition to defining and measuring outcomes such as adherence (exercise, self-management, diary, and medication use), exacerbation, hospitalizations, and patient satisfaction, the focus was also on including other outcomes relevant to health services and program planning such as safety, cost per patient and provider experience. Finally, this study extends previous reviews [42, 47, 48] by synthesizing findings according to type of technology and feedback provided.

This review concludes that HRQoL was not significantly improved with RHM as compared to usual care, regardless of monitoring technology; this finding is similar to previous reviews [42, 48, 49]. HRQoL is a complex construct, and while programs such as pulmonary rehabilitation consistently show improvement in HRQoL in COPD [50, 51], other disease management interventions (e.g., pharmaceutical care, patient education and action plan) do not consistently improve HRQoL in this disease [52, 53]. Unfortunately, no study was identified that used RHM during pulmonary rehabilitation. Instead, studies that included elements of pulmonary rehabilitation such as patient education, and/or exercise in both usual care and RHM groups, showed no greater benefit in HRQoL within the RHM group [19, 20, 22, 23]. These findings would suggest that regardless of the disease management program used, RHM did not improve HRQoL over and above usual care.

Remote home monitoring has the potential to improve disease self-management by making patients more aware of day-to-day changes in their symptoms and physical function [54, 55], thus improving disease management and reducing the risk of exacerbation. While previous studies have shown a significant reduction in health care utilization in COPD patients using self-management programs [56–58], this review found no consistent impact of RHM on patient self-efficacy, physician visits, ER visits or hospitalizations. Behaviour change is required for proper disease self-management, and time is required for patients to adopt and adhere to new behaviours. Most trials were under 12 months, and there may have been insufficient time to develop appropriate behaviour change that would lead to better disease management and reduced health care utilization.

Numerous studies have evaluated the impact of disease management programs in COPD, but due to heterogeneity in content, duration, and frequency of follow-ups, it is challenging to identify the key components of these programs. This review suggests that COPD related hospital admissions improved when RHM was coupled with feedback from healthcare professionals. No RCTs have investigated patient-provider communication in COPD specifically, but within other chronic disease states, more frequent and positive patient-provider communication was associated with improved health outcomes and higher levels of self-efficacy [59, 60]. A recent qualitative study aimed to explore the views of patients and healthcare professionals on telemonitoring found that patients and health care professionals considered relationship-based care important in COPD telemonitoring services [61]. Therefore, RHM that facilitates regular communication with a healthcare professional appears to be important.

While considered usual care, patients with COPD are often not referred to pulmonary rehabilitation. Several barriers, including lack of available programs and travel/transportation needs, prevent patients from attending conventional centre-based rehabilitation programs [62–64]. Home-based alternatives are needed, but these are currently underdeveloped and the complexity of COPD patients raises concerns regarding patient safety. Future studies should aim to evaluate the additional benefits of RHM in patients undergoing (virtual) pulmonary rehabilitation. Further work should also evaluate patient behaviour to determine if RHM is effective at changing key behaviours that are foundational to improved disease management.

Limitations
This systematic review has several limitations. One drawback of this review is the lack of its protocol registration in the PROSPERO database as recommended by guidelines [11, 12]. Any protocol changes were documented and discussed within the research group to minimize bias. Second, there is the possible risk of bias due to missing information in the included studies. Furthermore, included studies provided limited descriptions of the study randomization process, and the studies varied in components of the interventions. Third, the study was
restricted to English language studies, which might have led to the exclusion of possibly relevant studies. In addition, it was not possible to perform a meta-analysis on outcomes due to a high level of heterogeneity and limited data. Finally, there is the possibility of an impact on the findings by unpublished negative studies.

**Conclusion**

By applying objective, high-quality methods for gathering and synthesizing information from primary studies, this systematic review was conducted to review evidence from 19 studies, 17 of them RCTs, of remote home monitoring effectiveness in patients with COPD. Although a considerable amount of evidence to the effectiveness of RHM exists, due to heterogeneity of care settings, RHM components and the low-quality evidence, they should be interpreted with caution.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12913-022-07938-y.

Additional file 1: Table S1. Literature search results. Table S2. Characteristics of included studies. Table S3. Characteristics of participants included in the studies. Table S4. Remote home monitoring components. Table S5. Description of remote home monitoring programs and technology. Table S6. Remote home monitoring components. Table S7. Risk of bias. Table S8. Health-related quality of life - CAT, CCQ and other instruments. Table S9. Health-related quality of life - SGRQ. Table S10. Patient experience and satisfaction with RHM. Table S11. Frequency of exacerbations, Hospital admissions, ER visits and physician visits. Table S12. Adverse events and deaths during the follow-up period. Table S13. Exercise capacity and activity levels. Table S14. Mental health. Table S15. Self-efficacy. Table S16. Cost per patient. Table S17. Provider experience. Table S18. Lung function.

**Acknowledgements**

This work was supported by a financial contribution from the Government of Alberta. The views expressed herein do not necessarily represent the official policy of the Government of Alberta. The Health Technology & Policy Unit, School of Public Health, University of Alberta, receives a multiyear unrestricted grant from Alberta Health to conduct health evidence reviews to inform policy decisions in the province. We would also like to acknowledge Dr. Serena Humphries for her contributions to early work on this project and Becky Skidmore for the development of the search strategy.

**Author’s contributions**

FIN, TS and DM conceived the presented idea, initiated the project and were responsible for the design of the protocol. TS, FIN and MA did the review, data extraction, synthesis of results and quality assessment of studies. TS, FIN, MA, MS, EE and DM contributed to the analysis of the results. All authors discussed the results and contributed to the final manuscript. All authors have read and approved the manuscript.

**Funding**

The study received a grant from the Government of Alberta (grant number 008560). The funders had no role in the design and conduction of this study.

**Availability of data and materials**

All data relevant to the study are included in the article or uploaded as supplementary information.

**Declarations**

**Ethics approval and consent to participate**

The University of Alberta’s Research Ethics Office waived ethical approval.

**Consent for publication**

Not required.

**Competing interests**

None declared.

**Author details**

1 School of Public Health, Health Technology and Policy Unit, University of Alberta, 3-021 Research Transition Facility, Edmonton, AB T6G 2V2, Canada. 2 Alberta Health Services, Edmonton, AB, Canada. 3 Division of Pulmonary Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. 4 G.F. MacDonald Centre for Lung Health, Covenant Health, Edmonton, AB, Canada. 5 Facultly of Rehabilitation Medicine, University of Alberta, Edmonton, AB, Canada.

**Received:** 10 September 2021 **Accepted:** 31 March 2022

**Published online:** 14 May 2022

**References**

1. Sullivan S, Ramsey S, Lee T. The economic burden of COPD. Chronic Obstr Pulm Dis. 2000;117(2):5s–9s. https://doi.org/10.1002/7854707597.ch64.
2. Global initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2019 Report). 2019
3. Bolton CE, Waters CS, Peirce S, Elwyn G. Insufficient evidence of benefit: a systematic review of home telemonitoring for COPD. J Eval Clin Pract. 2011;17(6):1216–22. https://doi.org/10.1111/j.1365-2753.2010.01536.x.
4. Barnes PJ, Celli BR. Systemic manifestations and comorbidities. 2009;33(5):1165-1185. doi:https://doi.org/10.1186/09031936/33/28008
5. Donaldson GC, Seemungal TAR, Bhowmik A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. doi:https://doi.org/10.1136/thorax.57.10.847
6. Halpin DMG, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J COPD. 2012;7:653–61. https://doi.org/10.2147/COPD.S34186.
7. FitzGerald JM, Haddon JM, Bradley-Kennedy C, et al. Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J. 2007;14(3):145–52. https://doi.org/10.1155/2007/921914.
8. Iheanacho I, Zhang S, King D, Rizzo M, Islam A. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J COPD. 2020;15:439–60. https://doi.org/10.2147/COPD.S24942.
9. Tomsic I, Tomsic N, Trobac R, Krapan M, Kelava T. Continuous remote monitoring of COPD patients—justification and explanation of the requirements and a survey of the available technologies. Med Biol Eng Comput. 2018;56(4):547–69. https://doi.org/10.1007/s11517-018-1798-z.
10. Cooper CB, Sinchana W, Arnold MT, et al. Remote patient monitoring for the detection of COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2020;15:2005–13. https://doi.org/10.2147/COPD.S256907.
11. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Published online March 2021. www.training.cochrane.org/handbook
12. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
13. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75(January):40–6. https://doi.org/10.1016/j. jclinepi.2016.01.021.
14. Banks GC, Kepes S, Banks KP. Publication bias: the antagonist of meta-analytic reviews and effective policymaking. Educ Eval Policy Anal. 2012;34(3):255–77. https://doi.org/10.3310/0162373712446144.
51. Puhan MA, Gimeno-Santos E, Cates C, Troosters T. Pulmonary rehabilita-
     tion following exacerbations of chronic obstructive pulmonary disease.
     Cochrane Database Syst Rev. 2016;2016(12). doi:https://doi.org/10.1002/
     14651858.CD005305.pub4

52. Almagro P, Castro A. Helping COPD patients change health behavior in
     order to improve their quality of life. Int J COPD. 2013;8:335–45.

53. Lim JU, Park CK, Kim T, Jang A. The difficulty of improving quality of life
     in COPD patients with depression and associated factors. Int J Chron
     Obstruct Pulmon Dis. 2020;14:2331–41.

54. Morton K, Dennison L, May C, et al. Using digital interventions for self-
     management of chronic physical health conditions: a meta-ethnography
     review of published studies. Patient Educ Couns. 2017;100(4):616–22.
     https://doi.org/10.1016/j.pec.2016.10.019.

55. Walker RC, Tong A, Howard K, Palmer SC. Patient expectations and
     experiences of remote monitoring for chronic diseases: systematic
     review and thematic synthesis of qualitative studies. Int J Med Inform.
     2019;124(October):78–85. https://doi.org/10.1016/j.jmi.2019.01.013.

56. Sedeno MF, Nault D, Hamd DH, Bourbeau J. A self-management educa-
     tion program including an action plan for acute COPD exacerbations.
     COPD J Chronic Obstr Pulm Dis. 2009;6(5):352–8. https://doi.org/10.1080/
     15412550903150252.

57. Gadoury MA, Schwartzman K, Rouleau M, et al. Self-management
     reduces both short- and long-term hospitalisation in COPD. Eur Respir J.
     2005;26(5):853–7. https://doi.org/10.1183/09031936.05.00093204.

58. Bourbeau J, Saad N, Joubert A, et al. Making collaborative self-manage-
     ment successful in COPD patients with high disease burden. Respir Med.
     2013;107(7):1061–5. https://doi.org/10.1016/j.rmed.2013.03.003.

59. Kelley JM, Kraft-Todd G, Schapira I, Kossowsky J, Riess H. The influence
     of the patient-clinician relationship on healthcare outcomes: a systematic
     review and meta-analysis of randomized controlled trials. PLoS One.
     2014(9):9. doi:https://doi.org/10.1371/journal.pone.0094207

60. Ruben MA, Meterko M, Bokhour BG. Do patient perceptions of provider
     communication relate to experiences of physical pain? Patient Educ
     Couns. 2018;101(2):209–13. https://doi.org/10.1016/j.pec.2017.08.002.

61. Fairbrother P, Pinnock H, Hanley J, et al. Continuity, but at what cost?
     The impact of telemonitoring COPD on continuities of care: a qualitative
     study. Prim Care Respir J. 2012;21(3):322–8. https://doi.org/10.4104/pcrj.
     2012.00068.

62. Hayton C, Clark A, Olive S, et al. Barriers to pulmonary rehabilitation: char-
     acteristics that predict patient attendance and adherence. Respir Med.
     2013;107(3):401–7. https://doi.org/10.1016/j.rmed.2012.11.016.

63. Johnston KN, Young M, Grimmer KA, Antic K, Frith PA. Barriers to, and
     facilitators for, referral to pulmonary rehabilitation in COPD patients from
     the perspective of Australian general practitioners: a qualitative study.
     Prim Care Respir J. 2013;22(3):319–24. https://doi.org/10.4104/pcrj.2013.
     00062.

64. Camp PG, Hernandez P, Bourbeau J, et al. Pulmonary rehabilitation
     in Canada: a report from the Canadian thoracic society COPD clinical
     assembly. Can Respir J. 2015;22(3):147–52. https://doi.org/10.1155/2015/
     369851.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.